About: Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series
Creator	Miatello, Jordi Tissières, Pierre Pickkers, Peter Brumpt, Caren Dupuis, Claire Faivre, Valerie Leentjens, Jenneke Lukaszewicz, Anne Payen, Didier
source	PMC
abstract	BACKGROUND: The sepsis-induced immunodepression contributes to impaired clinical outcomes of various stress conditions. This syndrome is well documented and characterized by attenuated function of innate and adaptive immune cells. Several pharmacological interventions aimed to restore the immune response are emerging of which interferon-gamma (IFNγ) is one. It is of paramount relevance to obtain clinical information on optimal timing of the IFNγ-treatment, −tolerance, −effectiveness and outcome before performing a RCT. We describe the effects of IFNγ in a cohort of 18 adult and 2 pediatric sepsis patients. METHODS: In this open-label prospective multi-center case-series, IFNγ treatment was initiated in patients selected on clinical and immunological criteria early (< 4 days) or late (> 7 days) following the onset of sepsis. The data collected in 18 adults and 2 liver transplanted pediatric patients were: clinical scores, monocyte expression of HLA-DR (flow cytometry), lymphocyte immune-phenotyping (flow cytometry), IL-6 and IL-10 plasma levels (ELISA), bacterial cultures, disease severity, and mortality. RESULTS: In 15 out of 18 patients IFNγ treatment was associated with an increase of median HLA-DR expression from 2666 [IQ 1547; 4991] to 12,451 [IQ 4166; 19,707], while the absolute number of lymphocyte subpopulations were not affected, except for the decrease number of NK cells 94.5 [23; 136] to 32.5 [13; 90.8] (0.0625)]. Plasma levels of IL-6 464 [201–770] to 108 (89–140) ng/mL (p = 0.04) and IL-10 from IL-10 from 29 [12–59] to 9 [1–15] pg/mL decreased significantly. Three patients who received IFNγ early after ICU admission (<4 days) died. The other patients had a rapid clinical improvement assessed by the SOFA score and bacterial cultures that were repeatedly positive became negative. The 2 pediatric cases improved rapidly, but 1 died for hemorrhagic complication. CONCLUSION: Guided by clinical and immunological monitoring, adjunctive immunotherapy with IFNγ appears well-tolerated in our cases and improves immune host defense in sepsis induced immuno suppression. Randomized clinical studies to assess its potential clinical benefit are warranted.
has issue date	2019-11-05(xsd:dateTime)
bibo:doi	10.1186/s12879-019-4526-x
bibo:pmid	31690258
has license	cc-by
sha1sum (hex)	3d9b12f988b9c3311cbdf8a19c56ce343d91d210
schema:url	https://doi.org/10.1186/s12879-019-4526-x
resource representing a document's title	Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series
has PubMed Central identifier	PMC6833157
has PubMed identifier	31690258
schema:publication	BMC Infect Dis
resource representing a document's body	covid:3d9b12f988b9c3311cbdf8a19c56ce343d91d210#body_text
is schema:about of	named entity 'performing' named entity 'adaptive immune' named entity 'IMMUNODEPRESSION' covid:arg/3d9b12f988b9c3311cbdf8a19c56ce343d91d210 named entity 'immune response' named entity 'tolerance' named entity 'adult' named entity 'IFNγ' named entity 'innate' named entity 'effects' named entity 'clinical outcomes' named entity 'interferon gamma' named entity 'IFNγ' named entity 'IFNγ' named entity 'evolution' named entity 'Klebsiella' named entity 'lymphocyte' named entity 'supportive therapy' named entity 'graft rejection' named entity 'May 2004' named entity 'IL-10' named entity 'pharmacological' named entity 'IFNγ' named entity 'Aspergillus fumigatus' named entity 'IFNγ' named entity 'pediatric' named entity 'subcutaneous injection' named entity 'cardiopulmonary resuscitation' named entity 'primary end-point' named entity 'ICU' named entity 'downregulation' named entity 'fulminant hepatitis' named entity 'normal distribution' named entity 'IFNγ' named entity 'molecule' named entity 'sepsis' named entity 'IFNγ' named entity 'IFNγ' named entity 'methylprednisolone' named entity 'adverse events' named entity 'Cochin' named entity 'case series' named entity 'norepinephrine' named entity 'initial infection' named entity 'leukocyte' named entity 'IFNγ' named entity 'IFNγ' named entity 'HLA-DR' named entity 'primary infection' named entity 'IFNγ' named entity 'IFNγ' named entity 'San Diego CA' named entity 'IFNγ' named entity 'interquartile range' named entity 'innate immunity' named entity 'MHC class II' named entity 'immunosuppressive drugs' named entity 'randomized clinical trials' named entity 'intensive care' named entity 'anuric' named entity 'phenotyping' named entity 'phenotyping' named entity 'septic shock' named entity 'chronic granulomatous disease' named entity 'immunosuppression' named entity 'HLA-DR' named entity 'sepsis' named entity 'Netherlands' named entity 'HLA-DR' named entity 'informed consent' named entity 'IFNγ' named entity 'cfu' named entity 'NK cell'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software